Cervarix® [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] – Product Discontinuation

- GlaxoSmithKline announced the discontinuation of Cervarix [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] in the U.S. due to very low market demand.
  - The discontinuation is not due to product quality, safety, or efficacy concerns.
  - Existing stock of Cervarix can be distributed until the inventory is depleted. GSK's last ship date for Cervarix was August 31, 2016.
- Cervarix is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma *in situ*, and CIN grade 1.
- For further questions, contact the GSK Vaccine Service Center at **1-866-475-8222**.
- Other vaccines currently available for the prevention of HPV-related diseases include Gardasil® [HPV quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] and Gardasil® 9 [HPV 9-valent vaccine, recombinant]. Refer to the respective drug labels for detailed indication information.

Action Plan

- The discontinuation of Cervarix will be presented at an upcoming Pharmacy & Therapeutics Committee meeting.